Targeting glial physiology and glutamate cycling in the treatment of depression
- 1 September 2009
- journal article
- editorial
- Published by Elsevier in Biochemical Pharmacology
- Vol. 78 (5) , 431-439
- https://doi.org/10.1016/j.bcp.2009.04.008
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Target Identification for CNS Diseases by Transcriptional ProfilingNeuropsychopharmacology, 2008
- Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzoleMolecular Psychiatry, 2008
- Glial Loss in the Prefrontal Cortex Is Sufficient to Induce Depressive-like BehaviorsBiological Psychiatry, 2008
- Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and HippocampusJournal of Cerebral Blood Flow & Metabolism, 2008
- Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersNature Reviews Drug Discovery, 2008
- Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouseNeuroscience, 2008
- Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1European Journal of Pharmacology, 2007
- Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate functionBrain Research, 2007
- Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive SymptomsBiological Psychiatry, 2006
- Pro-survival signalling from the NMDA receptorBiochemical Society Transactions, 2006